BACKGROUND AND METHODS: We sought to describe the trends in survival from 1983 to 1989 among persons with the acquired immunodeficiency syndrome (AIDS) and to examine the relative effects on the natural history of AIDS of zidovudine use and demographic and clinical characteristics. This longitudinal, observational, population-based study used data from the Maryland Human Immunodeficiency Virus Information System, a data base that links information from the Maryland AIDS Registry with data on public and private health care claims, vital statistics, and hospital, long-term care, and ambulatory care records. RESULTS: The median survival after diagnosis among persons with AIDS (n = 1028) was 140 days longer for those given their diagnoses between 1987 and 1989 than for those given their diagnoses between 1983 and 1985 (450 vs 310 days). Among the 714 persons in whom AIDS was diagnosed after April 1987 (when zidovudine became available), two-year survival was greater among men than women (P less than 0.03), among persons less than 45 years old than among older persons (P less than 0.001), among non-Hispanic whites than among minorities (P less than 0.001), and among persons whose category of human immunodeficiency virus transmission was homosexual contact than among those with heterosexual, transfusion-related, or less common modes of transmission (P less than 0.02). In all the analyses the groups with the longer survival were more likely to have received zidovudine. The median survival among those who received zidovudine was 770 days, as compared with 190 days among those who never received the drug (P less than 0.001). By proportional-hazards analysis, zidovudine therapy was the factor most strongly associated with improved survival. CONCLUSIONS: For Maryland residents with AIDS there has been an improvement in survival since 1987. Zidovudine therapy and perhaps other aspects of care associated with it have contributed substantially to the improved survival.
Source Information
Johns Hopkins University School of Medicine, Department of Health and Mental Hygiene, Baltimore, MD.
This article has been cited by other articles:
Pakyz, A. L., Newberry, Y., Townsend, G. C.
(2003). Human Immunodeficiency Virus Infection: A Focus on Women. Journal of Pharmacy Practice
16: 170-181
[Abstract]
Anderson, K. H., Mitchell, J. M.
(2000). Differential Access in the Receipt of Antiretroviral Drugs for the Treatment of AIDS and Its Implications for Survival. Arch Intern Med
160: 3114-3120
[Abstract][Full Text]
Turner, B. J., Cunningham, W. E., Duan, N., Andersen, R. M., Shapiro, M. F., Bozzette, S. A., Nakazono, T., Morton, S., Crystal, S., St Clair, P., Stein, M., Zierler, S., for the HIV Cost and Services Utilization Study A,
(2000). Delayed Medical Care After Diagnosis in a US National Probability Sample of Persons Infected With Human Immunodeficiency Virus. Arch Intern Med
160: 2614-2622
[Abstract][Full Text]
Schwarcz, S. K., Hsu, L. C., Vittinghoff, E., Katz, M. H.
(2000). Impact of Protease Inhibitors and Other Antiretroviral Treatments on Acquired Immunodeficiency Syndrome Survival in San Francisco, California, 1987-1996. Am J Epidemiol
152: 178-185
[Abstract][Full Text]
Morgan, D, Malamba, S S, Orem, J, Mayanja, B, Okongo, M, Whitworth, J A G
(2000). Survival by AIDS defining condition in rural Uganda. Sex. Transm. Infect.
76: 193-197
[Abstract][Full Text]
Siegel, K., Raveis, V.
(1997). Perceptions of Access to HIV-Related Information, Care, and Services among Infected Minority Men. Qual Health Res
7: 9-31
[Abstract]
Collier, A. C., Coombs, R. W., Schoenfeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., Friedman, H. M., Merigan, T. C., Reichman, R. C., Hooper, C., Corey, L., The AIDS Clinical Trials Group,
(1996). Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine. NEJM
334: 1011-1018
[Abstract][Full Text]
Hogg, R. S., Craib, K., Montaner, J. S.G., Schechter, M. T., Turner, B. J., Markson, L. E., Fanning, T. R., Chaisson, R. E., Moore, R. D.
(1996). Race, Sex, Drug Use, and Human Immunodeficiency Virus Disease. NEJM
334: 123-124
[Full Text]
Chaisson, R. E., Keruly, J. C., Moore, R. D.
(1995). Race, Sex, Drug Use, and Progression of Human Immunodeficiency Virus Disease. NEJM
333: 751-756
[Abstract][Full Text]
KELLY, E.
(1995). Expanding Prisoners' Access to AIDS-Related Clinical Trials: An Ethical and Clinical Imperative. The Prison Journal
75: 48-68
[Abstract]
Lundgren, J D, Pedersen, C, Clumeck, N, Gatell, J M, Johnson, A M, Ledergerber, B, Vella, S, Phillips, A, Nielsen, J O
(1994). Survival differences in European patients with AIDS, 1979-89. BMJ
308: 1068-7103
[Abstract][Full Text]
Moore, R. D., Stanton, D., Gopalan, R., Chaisson, R. E.
(1994). Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community. NEJM
330: 763-768
[Abstract][Full Text]
Hirsch, M. S., D'Aquila, R. T.
(1993). Therapy for Human Immunodeficiency Virus Infection. NEJM
328: 1686-1695
[Full Text]
Brookmeyer, R
(1991). Reconstruction and future trends of the AIDS epidemic in the United States. Science
253: 37-42
[Abstract]
(1991). FURTHER EVIDENCE THAT ZIDOVUDINE EXTENDS LIFE IN AIDS. JWatch General
1991: 1-1
[Full Text]
Previous
